Eisai Presents Its Largest Real-World Study Of Anti-Epileptic Drug FYCOMPA® (perampanel) Across Patient Types At The 2021 American Epilepsy Society (AES) Annual Meeting

/PRNewswire/ -- Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...

Related Keywords

Japan ,United States ,South Korea ,American ,Perampanel Monotherapy ,Ivan Cheung ,Christopher Vancheri ,Manoj Malhotra ,Us Drug Enforcement Administration ,Linkedin ,American Epilepsy Society ,Twitter ,Eisai Inc ,Eisai Co Ltd ,Neurology Business Group ,Sustainable Development Goals ,American Epilepsy Society Meeting ,Global President ,Vice President ,Medical Affairs ,Extension Phase ,Safety Analysis Set ,Score Study ,Adult Epilepsy Patients Treated ,Everyday Clinical Practice ,World Experience ,Epilepsy Patients ,Elderly Epilepsy Patients ,Pooled Analysis ,Real World Studies ,Myoclonic Seizures ,Clinical Practice ,Health Related Quality ,Currently Untreated Recurrent Focal Seizures ,Term Efficacy ,Analysis Set ,North American Antiepileptic Drug ,Prescribing Information ,Enforcement Administration ,Sustainable Development ,